{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:53:04Z","timestamp":1791615184288,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14668-y","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:16:54Z","timestamp":1778062614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs"],"prefix":"10.1186","volume":"26","author":[{"given":"Jian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhebin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"14668_CR1","unstructured":"Stop TB, Partnership. Global Plan to End TB 2023\u20132030 [Internet]. Geneva: Stop TB Partnership; 2022 [cited 2024 Feb 20]. Available from: https:\/\/www.stoptb.org\/what-we-do\/advocate-endtb\/global-plan-end-tb\/global-plan-end-tb-2023-2030."},{"key":"14668_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/13571516.2020.1752044","volume":"27","author":"A Saha","year":"2020","unstructured":"Saha A, Roberts H. Pharmaceutical industry\u2019s changing market dynamics. Int J Econ Bus. 2020;27:159\u201375. https:\/\/doi.org\/10.1080\/13571516.2020.1752044.","journal-title":"Int J Econ Bus"},{"key":"14668_CR3","doi-asserted-by":"publisher","unstructured":"Mohseni S. Navigating market dynamics: insights from economics and market research. TMP Univers J Res Rev Arch. 2024;3(3). https:\/\/doi.org\/10.69557\/ujrra.v3i3.99.","DOI":"10.69557\/ujrra.v3i3.99"},{"key":"14668_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s11096-024-01767-1","volume":"46","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang K, Hua Y, Dong X, Zhang L. Impact and implications of national centralized drug procurement in China. Int J Clin Pharm. 2024;46:1557\u201362. https:\/\/doi.org\/10.1007\/s11096-024-01767-1.","journal-title":"Int J Clin Pharm"},{"key":"14668_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.14218\/JCTH.2022.00167","volume":"10","author":"X Zhao","year":"2022","unstructured":"Zhao X, Li M, Wang H, Xu X, Wu X, Sun Y, et al. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. J Clin Transl Hepatol. 2022;10:420\u20138. https:\/\/doi.org\/10.14218\/JCTH.2022.00167.","journal-title":"J Clin Transl Hepatol"},{"key":"14668_CR6","doi-asserted-by":"publisher","first-page":"804237","DOI":"10.3389\/fphar.2021.804237","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Ji X, Xiao H, Unger JM, Cai Y, Mao Z, et al. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. Front Pharmacol. 2021;12:804237. https:\/\/doi.org\/10.3389\/fphar.2021.804237.","journal-title":"Front Pharmacol"},{"key":"14668_CR7","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2023.7724","author":"B Zhao","year":"2023","unstructured":"Zhao B, Wu J. Impact of China\u2019s National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin. Int J Health Policy Manag. 2023;12:7724. https:\/\/doi.org\/10.34172\/ijhpm.2023.7724","journal-title":"Int J Health Policy Manag"},{"key":"14668_CR8","doi-asserted-by":"publisher","first-page":"e058064","DOI":"10.1136\/bmjopen-2021-054346","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Yang Y, Xu L, Mao Z, Cui D, Yang Y, et al. Impact of 4\u2009+\u20097 volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China. BMJ Open. 2022;12:e054346. https:\/\/doi.org\/10.1136\/bmjopen-2021-054346","journal-title":"BMJ Open"},{"key":"14668_CR9","doi-asserted-by":"publisher","first-page":"923209","DOI":"10.3389\/fphar.2022.923209","volume":"13","author":"J Lu","year":"2022","unstructured":"Lu J, Long H, Shen Y, Fang Y, Yang Y, Mao Z, et al. The change of drug utilization in China\u2019s public healthcare institutions under the 4\u2009+\u20097 centralized drug procurement policy: Evidence from a natural experiment in China. Front Pharmacol. 2022;13:923209. https:\/\/doi.org\/10.3389\/fphar.2022.923209.","journal-title":"Front Pharmacol"},{"key":"14668_CR10","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.3390\/ijerph17249415","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China. Int J Environ Res Public Health. 2020;17:9415. https:\/\/doi.org\/10.3390\/ijerph17249415.","journal-title":"Int J Environ Res Public Health"},{"key":"14668_CR11","doi-asserted-by":"publisher","first-page":"1392239","DOI":"10.3389\/fphar.2024.1392239","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Xu J. Does China\u2019s national volume-based drug procurement policy promote or hinder pharmaceutical innovation? Front Pharmacol. 2024;15:1392239. https:\/\/doi.org\/10.3389\/fphar.2024.1392239.","journal-title":"Front Pharmacol"},{"key":"14668_CR12","doi-asserted-by":"publisher","first-page":"1402581","DOI":"10.3389\/fpubh.2024.1402581","volume":"12","author":"J Li","year":"2024","unstructured":"Li J, Zhang X, Wang R, Cao K, Wan L, Ren X, et al. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises R&D investment: a difference-in-differences analysis in China. Front Public Health. 2024;12:1402581. https:\/\/doi.org\/10.3389\/fpubh.2024.1402581","journal-title":"Front Public Health"},{"key":"14668_CR13","doi-asserted-by":"publisher","first-page":"104595","DOI":"10.1016\/j.respol.2022.104595","volume":"51","author":"L Branstetter","year":"2022","unstructured":"Branstetter L, Chatterjee C, Higgins MJ. Generic competition and the incentives for early-stage pharmaceutical innovation. Res Policy. 2022;51(10):104595. https:\/\/doi.org\/10.1016\/j.respol.2022.104595","journal-title":"Res Policy"},{"key":"14668_CR14","doi-asserted-by":"publisher","first-page":"1227102","DOI":"10.3389\/fpubh.2023.1227102","volume":"11","author":"Z Sun","year":"2023","unstructured":"Sun Z, Na X, Chu S. Impact of China\u2019s National Centralized Drug Procurement Policy on pharmaceutical enterprises financial performance: a quasi-natural experimental study. Front Public Health. 2023;11:1227102. https:\/\/doi.org\/10.3389\/fpubh.2023.1227102.","journal-title":"Front Public Health"},{"key":"14668_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1186\/s12913-025-13449-3","volume":"25","author":"B Wang","year":"2025","unstructured":"Wang B, Xiao K, Xia H, Yu Q, Wang G, Huang R, et al. The impacts of the national volume-based procurement policy on the chronic disease medication market in China\u2019s public hospitals: a case study of medications for diabetes. BMC Health Serv Res. 2025;25:1279. https:\/\/doi.org\/10.1186\/s12913-025-13449-3.","journal-title":"BMC Health Serv Res"},{"key":"14668_CR16","doi-asserted-by":"publisher","first-page":"956823","DOI":"10.3389\/fpubh.2022.956823","volume":"10","author":"YJ Zhang","year":"2022","unstructured":"Zhang YJ, Ren Y, Zheng Q, Zhou L, Chen Y, Shi L, et al. The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China. Front Public Health. 2022;10:956823. https:\/\/doi.org\/10.3389\/fpubh.2022.956823","journal-title":"Front Public Health"},{"key":"14668_CR17","unstructured":"World Health Organization. Commercial determinants of health [Internet]. Geneva: World Health Organization. 2023 [cited 2025 Nov 12]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/commercial-determinants-of-health"},{"key":"14668_CR18","volume-title":"Industrial Organization","author":"JS Bain","year":"1959","unstructured":"Bain JS. Industrial Organization. New York: Wiley; 1959."},{"key":"14668_CR19","volume-title":"Industrial Market Structure and Economic Performance","author":"FM Scherer","year":"1990","unstructured":"Scherer FM, Ross D. Industrial Market Structure and Economic Performance. 3rd ed. Boston: Houghton Mifflin; 1990.","edition":"3"},{"key":"14668_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1355819614546032","volume":"20","author":"Y Feng","year":"2015","unstructured":"Feng Y, Pistollato M, Charlesworth A, Devlin N, Propper C, Sussex J. Association between market concentration of hospitals and patient health gain following hip replacement surgery. J Health Serv Res Policy. 2015;20(1):11\u20137. https:\/\/doi.org\/10.1177\/1355819614546032","journal-title":"J Health Serv Res Policy"},{"key":"14668_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12913-021-07458-1","volume":"22","author":"AS Vohra","year":"2022","unstructured":"Vohra AS, Jang SJ, Feldman DN, Kim LK. Hospital market concentration and the use of mechanical circulatory support devices in acute myocardial infarction complicated by cardiogenic shock. BMC Health Serv Res. 2022;22(1):89. https:\/\/doi.org\/10.1186\/s12913-021-07458-1","journal-title":"BMC Health Serv Res"},{"key":"14668_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/2168479015600205","volume":"50","author":"S Shibata","year":"2016","unstructured":"Shibata S, Uemura R, Suzuki T, Uemura R. Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area. Ther Innov Regul Sci. 2016;50(1):49\u201355. https:\/\/doi.org\/10.1177\/2168479015600205","journal-title":"Ther Innov Regul Sci"},{"key":"14668_CR23","doi-asserted-by":"publisher","first-page":"902025","DOI":"10.3389\/fpubh.2022.902025","volume":"10","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zhu J, Qiao J, Zhang D, Chen Y. The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies\u2014An Empirical Study Based on the Difference-in-Differences Model. Front Public Health. 2022;10:902025. https:\/\/doi.org\/10.3389\/fpubh.2022.902025","journal-title":"Front Public Health"},{"key":"14668_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhealeco.2015.09.001","volume":"44","author":"C Chatterjee","year":"2015","unstructured":"Chatterjee C, Kubo K, Pingali V. The consumer welfare implications of governmental policies and firm strategy in markets for medicines. J Health Econ. 2015;44:255\u201373. https:\/\/doi.org\/10.1016\/j.jhealeco.2015.09.001","journal-title":"J Health Econ"},{"key":"14668_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/hec.4239","volume":"30","author":"FR Lichtenberg","year":"2021","unstructured":"Lichtenberg FR. Are drug prices subject to creative destruction? Evidence from the US, 1997\u20132017. Health Econ. 2021;30:1346\u201362. https:\/\/doi.org\/10.1002\/hec.4239.","journal-title":"Health Econ"},{"key":"14668_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcpt.13551","volume":"47","author":"T Lan","year":"2022","unstructured":"Lan T, Guan L, Pang X, Gong Y, Song J, Li W, et al. Impact of the National Centralized Drug Procurement Policy (4\u2009+\u20097 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series. J Clin Pharm Ther. 2022;47:104\u201311. https:\/\/doi.org\/10.1111\/jcpt.13551.","journal-title":"J Clin Pharm Ther"},{"key":"14668_CR27","unstructured":"World Health Organization. WHO Model List of Essential Medicines \u2013 23rd list, 2023 [Internet]. Geneva: World Health Organization. 2023. WHO-MHP-HPS-EML-2023.02. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02. Accessed 1 Sep 2025."},{"key":"14668_CR28","doi-asserted-by":"publisher","first-page":"e064811","DOI":"10.1136\/bmjopen-2022-064811","volume":"13","author":"H Yi","year":"2023","unstructured":"Yi H, Shi F, Wang Z, Yang J, Li M, Guan X, et al. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis. BMJ Open. 2023;13:e064811. https:\/\/doi.org\/10.1136\/bmjopen-2022-064811.","journal-title":"BMJ Open"},{"key":"14668_CR29","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2022 [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. 2022. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 1 Sep 2025."},{"key":"14668_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2298\/pan140407025k","volume":"63","author":"A Krivka","year":"2016","unstructured":"Krivka A. On the concept of market concentration, the minimum Herfindahl\u2013Hirschman index, and its practical application. Panoeconomicus. 2016;63:525\u201340. https:\/\/doi.org\/10.2298\/pan140407025k","journal-title":"Panoeconomicus"},{"key":"14668_CR31","unstructured":"Marketing Study Guide. Market concentration and the Herfindahl-Hirschman Index [Internet]. Available from: https:\/\/www.marketingstudyguide.com\/market-concentration-herfindahl-hirschman-index\/. Accessed 1 Sep 2025."},{"key":"14668_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0003603x8202700302","volume":"27","author":"RA Miller","year":"1982","unstructured":"Miller RA. The Herfindahl-Hirschman Index as a Market Structure Variable: An Exposition for Antitrust Practitioners. Antitrust Bull. 1982;27:593\u2013618. https:\/\/doi.org\/10.1177\/0003603x8202700302.","journal-title":"Antitrust Bull"},{"key":"14668_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.21105\/joss.00828","volume":"3","author":"PD Waggoner","year":"2018","unstructured":"Waggoner PD. The hhi Package: Streamlined Calculation and Visualization of Herfindahl-Hirschman Index Scores. J Open Source Softw. 2018;3:828. https:\/\/doi.org\/10.21105\/joss.00828.","journal-title":"J Open Source Softw"},{"key":"14668_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.21776\/csefb.2022.01.3.08","volume":"1","author":"KA Khansa","year":"2022","unstructured":"Khansa KA, Shofwan. Perbandingan pengukuran struktur persaingan Herfindahl-Hirschman index dan concentration ratio industri perbankan Indonesia. Contemp Stud Econ Finance Bank. 2022;1:451\u201365. https:\/\/doi.org\/10.21776\/csefb.2022.01.3.08.","journal-title":"Contemp Stud Econ Finance Bank"},{"key":"14668_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.25140\/2410-9576-2019-3(19)-70-76","volume":"3","author":"NH Vyadrova","year":"2019","unstructured":"Vyadrova NH. Modern approaches for assessing the competition level in banking market. Sci Bull Polissia. 2019;3:70\u20136. https:\/\/doi.org\/10.25140\/2410-9576-2019-3(19)-70-76.","journal-title":"Sci Bull Polissia"},{"key":"14668_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25073\/2588-1116\/vnupam.4087","volume":"33","author":"D Dang","year":"2017","unstructured":"Dang D. The concentration and competition of Vietnam mobile telecommunications market through the HHI and the elasticity of demand. VNU J Sci Policy Manag Stud. 2017;33:1\u201315. https:\/\/doi.org\/10.25073\/2588-1116\/vnupam.4087.","journal-title":"VNU J Sci Policy Manag Stud"},{"key":"14668_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5539\/ijbm.v10n12p48","volume":"10","author":"A Diallo","year":"2015","unstructured":"Diallo A, Tomek G. The Interpretation of HH-Index Output Value When Used As Mobile Market Competitiveness Indicator. Int J Bus Manag. 2015;10:48\u201360. https:\/\/doi.org\/10.5539\/ijbm.v10n12p48.","journal-title":"Int J Bus Manag"},{"key":"14668_CR38","doi-asserted-by":"publisher","first-page":"106819","DOI":"10.1016\/j.tej.2020.106819","volume":"33","author":"R McCullough","year":"2020","unstructured":"McCullough R, Weisdorf M, Ende JC, Imon S. Exactly how inefficient is the PJM capacity Market? Electr J. 2020;33:106819. https:\/\/doi.org\/10.1016\/j.tej.2020.106819.","journal-title":"Electr J"},{"key":"14668_CR39","doi-asserted-by":"publisher","first-page":"012047","DOI":"10.1088\/1755-1315\/766\/1\/012047","volume":"766","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang Y, Zhang X, Wen Y, Xu Q, Xiao K, et al. Research on evaluation index system of the operation efficiency in electricity market. IOP Conf Ser: Earth Environ Sci. 2021;766:012047. https:\/\/doi.org\/10.1088\/1755-1315\/766\/1\/012047.","journal-title":"IOP Conf Ser: Earth Environ Sci"},{"key":"14668_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1553-779x.1195","volume":"6","author":"T Chandarasupsang","year":"2006","unstructured":"Chandarasupsang T, Siewierski T, Galloway S, Burt G, McDonald J. An Application of HHI to Study Electricity Market Design Issues. Int J Emerg Electr Power Syst. 2006;6:1\u201315. https:\/\/doi.org\/10.2202\/1553-779x.1195.","journal-title":"Int J Emerg Electr Power Syst"},{"key":"14668_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1377\/hlthaff.23.6.25","volume":"23","author":"DA Hyman","year":"2004","unstructured":"Hyman DA, Kovacic WE, Monopoly. Monopsony, And Market Definition: An Antitrust Perspective On Market Concentration Among Health Insurers. Health Aff. 2004;23:25\u20138. https:\/\/doi.org\/10.1377\/hlthaff.23.6.25.","journal-title":"Health Aff"},{"key":"14668_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hec.814","volume":"13","author":"E Nauenberg","year":"2004","unstructured":"Nauenberg E, Alkhamisi M, Andrijuk Y. Simulation of a Hirschman\u2013Herfindahl index without complete market share information. Health Econ. 2004;13:87\u201394. https:\/\/doi.org\/10.1002\/hec.814.","journal-title":"Health Econ"},{"key":"14668_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7326\/m16-1432","volume":"167","author":"CV Dave","year":"2017","unstructured":"Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High Generic Drug Prices and Market Competition. Ann Intern Med. 2017;167:145\u201351. https:\/\/doi.org\/10.7326\/m16-1432.","journal-title":"Ann Intern Med"},{"key":"14668_CR44","doi-asserted-by":"publisher","first-page":"l5274","DOI":"10.1136\/bmj.l5274","volume":"366","author":"A O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell A, Anderson P, Jan\u00e9-Llopis E, Manthey J, Kaner E, Rehm J. Immediate impact of minimum unit pricing on alcohol purchases in Scotland: controlled interrupted time series analysis for 2015\u201318. BMJ. 2019;366:l5274. https:\/\/doi.org\/10.1136\/bmj.l5274.","journal-title":"BMJ"},{"key":"14668_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/biomet\/37.3-4.409","volume":"37","author":"J Durbin","year":"1950","unstructured":"Durbin J, Watson GS. Testing for serial correlation in least squares regression. Biometrika. 1950;37:409\u201328. https:\/\/doi.org\/10.1093\/biomet\/37.3-4.409.","journal-title":"Biometrika"},{"key":"14668_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/1536867X1501500208","volume":"15","author":"A Linden","year":"2015","unstructured":"Linden A. Conducting interrupted time-series analysis for Single- and multiple-group comparisons. Stata J. 2015;15:480\u2013500. https:\/\/doi.org\/10.1177\/1536867X1501500208.","journal-title":"Stata J"},{"key":"14668_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a Tutorial. Int J Epidemiol. 2017;46:348\u201355. https:\/\/doi.org\/10.1093\/ije\/dyw098.","journal-title":"Int J Epidemiol"},{"key":"14668_CR48","doi-asserted-by":"publisher","first-page":"e011535","DOI":"10.1136\/bmjgh-2022-011535","volume":"8","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Wang Q, Sun Q, Lexchin J, Yang L. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Glob Health. 2023;8:e011535. https:\/\/doi.org\/10.1136\/bmjgh-2022-011535.","journal-title":"BMJ Glob Health"},{"key":"14668_CR49","unstructured":"The Global Fund to Fight AIDS. Tuberculosis and Malaria. Price and Quality Reporting (PQR) [Internet]. Geneva: The Global Fund; 2025 [cited 2026 Jan 16]. Available from: https:\/\/pqr.theglobalfund.org\/."},{"key":"14668_CR50","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.2147\/IDR.S256128","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Liu X, Yang L, Zhang G, Gu Z, Chen Z, Sun J. Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China. Infect Drug Resist. 2020;13:3679\u201387. https:\/\/doi.org\/10.2147\/IDR.S256128.","journal-title":"Infect Drug Resist"},{"key":"14668_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12992-024-01047-7","volume":"20","author":"S Kohler","year":"2024","unstructured":"Kohler S, Achar J, Mulder C, Sitali N, Paul N. Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024. Global Health. 2024;20:51. https:\/\/doi.org\/10.1186\/s12992-024-01047-7.","journal-title":"Global Health"},{"key":"14668_CR52","unstructured":"Stop TB Partnership. Breaking News: Historical Drop of DR-TB Treatment Cost Below $300 After Third Major Cut in 2025 [Internet]. Geneva: Stop TB Partnership; 2025 [cited 2026 Jan 16]. Available from: https:\/\/www.stoptb.org\/news\/breaking-news-historical-drop-dr-tb-treatment-cost-below-300-after-third-major-cut-2025-stop."},{"key":"14668_CR53","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/00036846.2024.2399818","volume":"57","author":"H Liu","year":"2024","unstructured":"Liu H, Fang X. Influence of Chinese National Centralized Drug Procurement policy on pharmaceutical corporate R&D investment. Appl Econ. 2024;57:1395\u2013414. https:\/\/doi.org\/10.1080\/00036846.2024.2399818.","journal-title":"Appl Econ"},{"key":"14668_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.54097\/h0ye7k84","volume":"9","author":"Y Liao","year":"2024","unstructured":"Liao Y, Fan Q, Wang Y, Drug Procurement. R&D Models, and Innovation Performance of Pharmaceutical Companies. J Innov Dev. 2024;9:53\u201361. https:\/\/doi.org\/10.54097\/h0ye7k84.","journal-title":"J Innov Dev"},{"key":"14668_CR55","doi-asserted-by":"publisher","first-page":"12037","DOI":"10.3390\/ijerph182212037","volume":"18","author":"Y Hu","year":"2021","unstructured":"Hu Y, Chen S, Qiu F, Chen P, Chen S. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms\u2019 R&D Investment in China? An Event Study Approach. Int J Environ Res Public Health. 2021;18:12037. https:\/\/doi.org\/10.3390\/ijerph182212037.","journal-title":"Int J Environ Res Public Health"},{"key":"14668_CR56","doi-asserted-by":"publisher","first-page":"107590","DOI":"10.1016\/j.frl.2025.107590","volume":"82","author":"S Liang","year":"2025","unstructured":"Liang S. Bank competition, market concentration and innovation: Insights from China\u2019s patent pledge financing policy. Finance Res Lett. 2025;82:107590. https:\/\/doi.org\/10.1016\/j.frl.2025.107590.","journal-title":"Finance Res Lett"},{"key":"14668_CR57","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/joclec\/nhad012","volume":"19","author":"G Koltay","year":"2023","unstructured":"Koltay G, Lorincz S, Valletti T. Concentration and Competition: Evidence From Europe and Implications For Policy. J Compet Law Econ. 2023;19:466\u2013501. https:\/\/doi.org\/10.1093\/joclec\/nhad012.","journal-title":"J Compet Law Econ"},{"key":"14668_CR58","doi-asserted-by":"publisher","first-page":"106338","DOI":"10.1016\/j.econmod.2023.106338","volume":"125","author":"Z Yu","year":"2023","unstructured":"Yu Z, Cheng J, Mukhopadhaya P, Wu H. Do information spillovers across products aggravate product market monopoly? An examination with Chinese data. Econ Model. 2023;125:106338. https:\/\/doi.org\/10.1016\/j.econmod.2023.106338.","journal-title":"Econ Model"},{"key":"14668_CR59","doi-asserted-by":"publisher","first-page":"e33198","DOI":"10.1016\/j.heliyon.2024.e33198","volume":"10","author":"Z Ke","year":"2024","unstructured":"Ke Z, Zhang Y, Duan D. Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises. Heliyon. 2024;10:e33198. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33198.","journal-title":"Heliyon"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14668-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:59:31Z","timestamp":1779803971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14668-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14668"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14668-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study solely encompasses information related to drug procurement. All data have undergone anonymization and do not contain any personally identifiable information. Moreover, the database contains no individual patient-level data or patient identifiers. Individual hospital identities were further anonymized in our analysis. As this study involved only secondary analysis of aggregated procurement data without any patient-level information, ethical approval was not required according to national regulations. In accordance with the Personal Information Protection Law of the People's Republic of China (adopted by the Standing Committee of the 13th National People's Congress on August 20, 2021, and effective from November 1, 2021) and the Measures for the Ethical Review of Biomedical Research Involving Humans (Trial) stipulated by the National Health Commission of the People's Republic of China in 2007, given that this study does not involve human participation, human tissues, or identifiable personal data, the ethics review committee of this institution (Peking University) explicitly states that ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"756"}}